AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06148259 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of prostate volume
Description: Measurements using ultrasound
Study NCT06148259 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pittsburgh sleep quality Index
Description: Questionnaire to assess quality of sleep
Study NCT06148259 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Glycated hemoglobin
Description: Measures control of diabetes
Study NCT05034575 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eye Tracking Technology Sensor
Description: Eye tracking will be performed using Tobii Pro eye tracking technology sensor (Tobii Pro Fusion, Stockholm, Sweden), providing binocular eye tracking up to 250 Hz. The sensor, positioned on the inferior aspect of the computer monitor, reflects infrared (IR) light beams off of each cornea and are subsequently captured.
Study NCT06270511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-337395
Description: Administered as an oral suspension.
Study NCT06270511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as an oral suspension.
Study NCT04885530 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
Study NCT05267015 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gingival coverage using coronally advanced flap and a connective tissue graft
Description: A coronally advanced flap is applied for recession coverage in the maxilla in a split-mouth randomized trial using a subepithelial connective tissue graft
Study NCT05267015 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gingival coverage using coronally advanced flap and platelet rich fibrin membranes
Description: A coronally advanced flap is applied for recession coverage in the maxilla in a split-mouth randomized trial using platelet rich fibrin membranes
Study NCT05004779 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: human stem cell conditioned media was applied after non-ablative laser therapy
Description: After laser treatment on hypertrophic scars, human stem cell media was applied to one side
Study NCT05004779 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: normal saline was applied after non ablative laser therapy
Description: physiological saline was applied to the other side.
Study NCT06417905 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised exercises
Description: strengthening deep neck flexors, serratus anterior middle and lower trapez stretchening upper trapezius, levator scapula
Study NCT06417905 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video based exercises
Description: strengthening deep neck flexors, serratus anterior middle and lower trapez stretchening upper trapezius, levator scapula
Study NCT04885530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Montelukast sodium is a white to off-white powder. The 10 mg montelukast tablets are beige, rounded square-shaped, biconvex, film-coated tablets. Each tablet contains 10.4 mg of montelukast sodium, which is equivalent to 10 mg montelukast. All packaging will be labeled to indicate that the product is for investigational use.
Study NCT04885530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin IR tablets contain the active metformin hydrochloride and inactive ingredients including povidone and magnesium stearate. Commercially available metformin 500 mg tablets will be provided.
Study NCT05278715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Dose of carboplatin is adjusted for age (over 1 year old, full dose, 220 mg/m\^2; 6 months of age or less, 66 percent of the full dose; 7 to 12 months of age, 80 percent).
Study NCT05278715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Dose of vincristine is adjusted for age (over 1 year old, full dose, 1.5 mg/m\^2; 6 months of age or less, 66 percent of the full dose; 7 to 12 months of age, 80 percent). Maximum dose is 2 mg.
Study NCT05278715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human endostatin
Description: Recombinant human endostatin (rh-ES) is administrated at a dose of 15mg daily, for 14 consecutive days every 3 weeks.
Study NCT04600622 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rural Diabetes One-Day Education and Care program (R-D1D)
Description: One time, 5.5-hour multi-disciplinary diabetes self-management education and support intervention delivered via telehealth.
Study NCT04600622 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Education Materials
Description: Diabetes Education Materials
Study NCT05557435 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breast milk odor
Description: The intervention of the experimental group was to stimulate the odor of breast milk. The researchers informed the mothers of premature infants in advance on the day before the experiment, and collected the breast milk samples in the morning before eating on the day of the experiment (excluding the influence of the odor of breast milk by diet). The researchers took a clean cotton ball so that the breast milk was completely absorbed by the cotton ball, and placed the cotton ball that absorbed breast milk at a distance of 5cm next to the mouth and nose of the premature infant, so that the premature infant could receive the smell of breast milk.~The intervention of the control group was to stimulate the smell of distilled water.
Study NCT05557435 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06145607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-CLS-7262
Description: ABBV-CLS-7262
Study NCT05957055 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: parental training in behavior management
Description: Parental training in behavior management - online group sessions (4-6 families within group) with trained specialist, 10 once-weekly sessions. To continue to pharmacotherapy, the parents/legal guardians are required to participate in at least 8 out of 10 sessions.
Study NCT05957055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisdexamfetamine
Description: Once-daily pharmacotherapy with lisdexamfetamine (608137-32-2, SUB32146), administered orally, for a duration of 6 months with initial dose of 30mg and dose optimization for 5-7 weeks (visits after 1st, 3rd and 5th week of therapy to adjust dose, in 20mg steps).
Study NCT05957055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: Once-daily pharmacotherapy with methylphenidate (prolonged-release tablet, 298-59-9, SUB03254MIG), administered orally, for a duration of 6 months with initial of 18mg dose optimization for 5-7 weeks (visits after 1st, 3rd and 5th week of therapy to adjust dose, in 18mg steps).
Study NCT04409080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN7257
Description: Administered by intravenous (IV) infusion, in Part A and B.
Study NCT05300152 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulpotomy procedure and Histological evaluation
Description: Sixty primary teeth in thirty children aged 7-9 years selected from Outpatient dental clinic Pedodontic and Endodontic Departments, Suez Canal University. divided into group I includes 30 teeth treated with ACTIVA BioACTIVE Base/Liner and group II includes 30 teeth treated by MTA with standard pulpotomy procedure Patients will be recalled after 15 and 30-days . 15 teeth from group I and 15 teeth from group II will be extracted after 15 days then subjected to decalcification then15 teeth from group I and 15 teeth from group II will be extracted after 30 days \& subjected to decalcification procedure in 20% EDTA at 4 °C for approximately 5 weeks then embedded in paraffin. Serial sections will be cut at 5 µm thickness. Deparaffinize the sections by 2 changes of xylene for 10 minutes each. Stain in Harris hematoxylin solution for 8 minutes. mount with xylene based mounting medium for conventional histological assessment using light microscope
Study NCT05300152 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pulpotomy procedure and Histological evaluation
Description: Sixty primary teeth in thirty children aged 7-9 years selected from Outpatient dental clinic Pedodontic and Endodontic Departments, Suez Canal University. divided into group I includes 30 teeth treated with ACTIVA BioACTIVE Base/Liner and group II includes 30 teeth treated by MTA with standard pulpotomy procedure Patients will be recalled after 15 and 30-days . 15 teeth from group I and 15 teeth from group II will be extracted after 15 days then subjected to decalcification then15 teeth from group I and 15 teeth from group II will be extracted after 30 days \& subjected to decalcification procedure in 20% EDTA at 4 °C for approximately 5 weeks then embedded in paraffin. Serial sections will be cut at 5 µm thickness. Deparaffinize the sections by 2 changes of xylene for 10 minutes each. Stain in Harris hematoxylin solution for 8 minutes. mount with xylene based mounting medium for conventional histological assessment using light microscope
Study NCT05300152 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Immunohistochemistry Protocol for Fibronectin Antibody
Description: 1. Deparaffinization/Rehydration~   * Slides heated in an oven at 65C for 1 hour.~  * De-paraffinization~2. Antigen Retrieval~   * Immersion of slides into staining dish containing Antigen Retrieval Solution.~  * Placing the staining dish into rice cooker.~  * When turned to warm, unplug cooker~  * Allow to cool down for 20 min~3. Staining~   * Wash slides with TBST for 5 min on a shaker.~  * Inactivate endogenous peroxidase by 3% hydrogen peroxide for 10 min.~  * Block slides with blocking solution for 1 hour.~  * Dilute primary antibody in blocking buffer~  * Apply primary antibody to each section and incubate overnight in humidified chamber~  * Wash slides three times with TBST
Study NCT05300152 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Immunohistochemistry Protocol for Fibronectin Antibody
Description: 1. Deparaffinization/Rehydration~   * Slides heated in an oven at 65C for 1 hour.~  * De-paraffinization~2. Antigen Retrieval~   * Immersion of slides into staining dish containing Antigen Retrieval Solution.~  * Placing the staining dish into rice cooker.~  * When turned to warm, unplug cooker~  * Allow to cool down for 20 min~3. Staining~   * Wash slides with TBST for 5 min on a shaker.~  * Inactivate endogenous peroxidase by 3% hydrogen peroxide for 10 min.~  * Block slides with blocking solution for 1 hour.~  * Dilute primary antibody in blocking buffer~  * Apply primary antibody to each section and incubate overnight in humidified chamber~  * Wash slides three times with TBST
Study NCT05300152 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Immunohistochemistry Protocol for Osteopontin Antibody
Description: will be carried out via avidin-biotin-peroxidase complex method using a VECTASTAIN ABC Kit . Sections will be deparaffinized by xylene and graded ethanol then treated with 20 µg/ml Proteinase K for 10 min. to prevent endogenous peroxidase activity, sections is incubated for 30 min in 0.3% H2O2/methanol then treated with 0.1% blocking serum albumin and incubated with primary antibody for 30 min. Rabbit polyclonal anti-osteopontin and goat polyclonal anti-RANKL will be used. dilution of primary antibodies used will be osteopontin (1 : 6000-8000). After being washed with phosphate-buffered saline several times, sections will be incubated with biotinylated IgG for 30 min and subsequently with streptavidin-horseradish peroxidase for 30 min. Following several washes with phosphate-buffered saline, 3,3'-diaminobenzidine substrate will be applied. As a negative control, non-immune serum will be used instead of primary antibody.
Study NCT05300152 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Immunohistochemistry Protocol for Osteopontin Antibody
Description: will be carried out via avidin-biotin-peroxidase complex method using a VECTASTAIN ABC Kit . Sections will be deparaffinized by xylene and graded ethanol then treated with 20 µg/ml Proteinase K for 10 min. to prevent endogenous peroxidase activity, sections is incubated for 30 min in 0.3% H2O2/methanol then treated with 0.1% blocking serum albumin and incubated with primary antibody for 30 min. Rabbit polyclonal anti-osteopontin and goat polyclonal anti-RANKL will be used. dilution of primary antibodies used will be osteopontin (1 : 6000-8000). After being washed with phosphate-buffered saline several times, sections will be incubated with biotinylated IgG for 30 min and subsequently with streptavidin-horseradish peroxidase for 30 min. Following several washes with phosphate-buffered saline, 3,3'-diaminobenzidine substrate will be applied. As a negative control, non-immune serum will be used instead of primary antibody.
Study NCT05571514 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mother-of-pearl
Description: The mother-of-pearl, derived from the inner shell of marine molluscs, is composed of calcium carbonate and organic compounds, some of which peptides are active on the bone.~The mineralization inducing activity of the molecules extracted from the mother-of-pearl has been shown in vitro. Mother-of-pearl extract also contains molecules that inhibit the resorption activity of osteoclasts. Mother-of-pearl compounds can thus slow bone remodelling as showed in an ovariectomy-induced osteoporosis model in rat, where mother-of-pearl supplementation showed a better effect on limitation of bone loss than calcium carbonate supplementation.
Study NCT05848284 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VDyne Transcatheter Tricuspid Valve Replacement System
Description: The study investigational device is the VDyne Transcatheter Tricuspid Valve Replacement System which consists of a bioprosthetic implantable tricuspid valve, the VDyne Delivery System, Drop Tether, accessories that facilitate the placement of the valve and the VDyne Retrieval System. The VDyne Valve is deployed by transfemoral implantation within the native tricuspid valve and is implanted under fluoroscopic and transesophageal echocardiography (TEE) guidance, while the heart remains beating, without the use of CPB. The valve is repositionable and fully retrievable intraoperatively. Repositioning allows optimization of the valve position following deployment, and retrieval, with the VDyne Retrieval System, allows use of an alternative valve size or removal of the index VDyne Valve in the event of suboptimal valve delivery or other intraoperative complication.
Study NCT05571514 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Carbonate
Description: Calcium carbonate is a source of calcium.
Study NCT05740826 — intervention group
Intervention type: DEVICE
Intervention: Algometer
Description: The algometer head was applied to the trigger point of selected muscles at an angle of 90° and, increasing the pressure at a speed of about 100g/s, three measurements were made. Each measurement stoped at the first sensation of pain
Study NCT06308926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG-001 (Low-dose)
Description: MRG-001 is subcutaneously administered.
Study NCT06308926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG-001 (High-dose)
Description: MRG-001 is subcutaneously administered.
Study NCT06308926 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline placebo will be administered subcutaneously based on bodyweight and similar dose as the treatment group.
Study NCT06612151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YL201
Description: Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks (Q3W) as a cycle at RP3D dose level.
Study NCT06612151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topotecan hydrochloride for injection
Description: Topotecan hydrochloride will be administered intravenously per prescribing information.
Study NCT04792216 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wild Salmon
Description: Wild salmon fillets
Study NCT04792216 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Farmed Salmon
Description: Farm salmon fillets
Study NCT06497946 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SlimTrack Plataform
Description: SlimTrack Plataform requests log in and includes anthropometric data of participants, besides answers about questionaires and other tasks in online content available
Study NCT06497946 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet prescription
Description: Nutrition Professional evaluates diet habits and prescribes a reeducation method in order to fulfill better behavior towards food intake
Study NCT05817279 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Optical coherence tomography
Description: Optical coherence tomography: OCT is a non-invasive CE-certified diagnostic modality based on light interferometry. An OCT scan visualizes an area with a diameter of 6mm thereby revealing the skin and adnexal structures with a depth of approximately 1.5mm.~3mm punch biopsy: the patients included in this study underwent a 3mm punch biopsy conform regular care. The subsequent histopathological examination of the biopsy specimen serves as ground truth diagnosis of the lesions (gold standard)
Study NCT05522387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XPro1595
Description: Each enrolled patient will be treated with 1.0 mg/kg of XPro1595 as a subcutaneous injection once a week for 55, or 74 weeks, for a total exposure to XPro1595 of up to 78 weeks (18 months), depending on their previous study.
Study NCT04913766 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Management Plus
Description: Five session psychological intervention focusing on problem management skills.
Study NCT04913766 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Services as Usual
Description: Mental health services provided by a mental health specialists according to their standard practices of care
Study NCT04974918 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Facial Artery Perforator-Based Nasolabial Flaps in The Reconstruction of large Lip defects post traumatic or post tumor resection.
Description: A perforator near the defect was selected to accomplish a sufficient arc of rotation without tension. The flap was designed to cover the defect based on one perforator and to hide the donor site in the nasolabial fold. An incision on one side of the flap was made to the subcutaneous tissue. Undermining of the flap until the perforators were identified. After the perforators were identified, the flap was redesigned and an incision was made circumferentially. Dissection of the pedicle was performed until tension-free transposition was done to cover the defect, and the distal perforators were sacrificed to help flap movement.
Study NCT05307731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: 0.5mg daily for 90-180 days, in addition to guideline-based treatment for DM
Study NCT05307731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: guideline-based treatment for DM
Description: guideline-based treatment for DM
Study NCT05307731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: guideline-based treatment for DM
Description: guideline-based treatment for DM
Study NCT05998278 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Personalized Optimization of Systematic Prostate Biopsy
Description: Login the model based on our previous study (https://daringsky.shinyapps.io/prediction_v2/) allows for input of age, BMI, serum PSA, size and location of suspicious lesions, PIRADS - V2 score, and prostate volume to generate an individualized needle distribution map,then targeted biopsy combined personalized optimization of systematic prostate biopsy was performed.
Study NCT05086744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iptacopan
Description: Iptacopan 200 mg BID
Study NCT06259708 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low intensity focused ultrasound
Description: Sonication with low intensity focused ultrasound in two deep brain structures (ZI and Vim).
Study NCT05109052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXS-5505 and Atezolizumab and Bevacizumab
Description: Open label safety and tolerability assessment of PXS-5505 incorporating first-line combination therapy Atezolizumab and Bevacizumab
Study NCT03622528 — intervention group
Intervention type: RADIATION
Intervention: Chest CT scan
Description: Standard dose chest CT scan
Study NCT05914116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DB-1311
Description: Administered I.V.
Study NCT05922046 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leap Motion Controller on flat display
Description: The LMC is a device with a Universal Serial Bus (USB) device capable of detecting the movement of hands and fingers. It is small in size and you need to connect the USB device to the computer and place your hands above the LMC. First, training will be carried out with the Leap Motion Controller instrument for 5 minutes, for a presentation and interaction with it, in the initial meeting. From the second meeting, the service protocol will be 16 sessions, this time being distributed as: first game lasting 7 minutes, second and third games lasting 6 minutes each and the last game lasting 8 minutes, totaling 27 minutes of intervention. Between games, about 2 minutes of rest was adopted. They were chosen through the website www.leapmotion.com¸ in order to relate them to the functional movements of the upper limbs in daily life tasks.
Study NCT04110262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High dietary sodium intake
Description: Fourteen day feeding period of high dietary sodium (3400 mg/day)